GLP1R and type 2 diabetes mellitus: At present, four DPP-IV inhibitors (Sitagliptin, Vildagliptin, Saxagliptin, and Linagliptin) and two GLP-1 receptor agonists (Exenatide and Liraglutide) are approved for the treatment of T2DM.